| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 05/28/1997 | EP0774974A1 Novel vaccine adjuvant and vaccine |
| 05/28/1997 | EP0774959A1 A liposomal delivery system for biologically active agents |
| 05/28/1997 | EP0546092B1 Therapeutic ribozyme compositions |
| 05/28/1997 | DE19623203A1 Virusvektor für den Transfer stabiler Episome Virus vector for the transfer of stable episomes |
| 05/28/1997 | DE19543628A1 Humanes, im Blut zirkulierendes Peptid mit insulinotroper Wirkung (GCAP-II-(89-112), (Guanylyl Cyclase C Aktivierendes Peptid II) und seine GCAP-Analoga, insbesondere das GCAP-I-(99-115), seine Anwendung als pharmakologischer Wirkstoff und Benutzung seines Wirkungsprinzipes zur Bereitstellung neuer GC-C-abhängiger insulinotroper Wirkstoffe Human, circulating in the blood insulinotropic peptide effect (GCAP-II (89-112), (guanylyl cyclase-activating peptide C II) and its GCAP analogues, in particular the GCAP-I (99-115), its use as a pharmacological drug use and its effect principle to provide new GC-C-dependent insulinotropic drugs |
| 05/28/1997 | DE19543553A1 VP-Antigene des JC-Virus VP-antigens of the JC virus |
| 05/28/1997 | CN1150820A Manipulation of protoporphyrinogen oxidase enzyme activity in eukaryotic organisms |
| 05/28/1997 | CN1150804A Fibroblast growth factor-10 |
| 05/28/1997 | CN1150754A Human osteoclast-derived cathepsin |
| 05/27/1997 | US5633395 Chemically-defined non-polymeric valency platform molecules and conjugates thereof |
| 05/27/1997 | US5633234 Lysosomal targeting of immunogens |
| 05/27/1997 | US5633227 Secretory leukocyte protease inhibitor as an inhibitor of tryptase |
| 05/27/1997 | US5633147 Transforming growth factor αH1 |
| 05/27/1997 | US5632994 Fas associated proteins |
| 05/22/1997 | WO1997018332A1 Regulation of cancer-causing tyrosine kinases by potassium ion conductance |
| 05/22/1997 | WO1997018319A1 Joint expression of gtp cyclohydrolase and tyrosine hydroxylase |
| 05/22/1997 | WO1997018318A1 Method for gene introduction into target cells by retrovirus |
| 05/22/1997 | WO1997018317A1 Dodecahedral adenoviral protein complex, composition containing same and uses thereof |
| 05/22/1997 | WO1997018312A1 Chimeric oligomers having an rna-cleavage activity |
| 05/22/1997 | WO1997018305A2 Method to prepare drug-resistant, non-malignant hematopoietic cells |
| 05/22/1997 | WO1997018304A1 Methods for modulation of cholesterol transport |
| 05/22/1997 | WO1997018300A2 Murine model for human carcinoma |
| 05/22/1997 | WO1997018241A1 Inducing resistance to tumor growth with soluble igf-1 receptor |
| 05/22/1997 | WO1997018237A1 Chemokine from niddm pancreas |
| 05/22/1997 | WO1997018232A2 Peptides derived from the oncogene proteine bcr-abl expressed by leukemic cells and utilisation thereof for the therapy of human leukemiae |
| 05/22/1997 | WO1997018185A1 Lipopolyamines as transfection agents and pharmaceutical uses thereof |
| 05/22/1997 | WO1997017994A1 Treatment of diabetes with a glucokinase gene |
| 05/22/1997 | WO1997017983A1 Methods of treating disorders of non-visual sensory epithelia |
| 05/22/1997 | WO1997017982A1 Methods and compositions for hair growth promotion |
| 05/22/1997 | WO1997017979A1 Methods for diagnosis and treatment of bloom's syndrome |
| 05/22/1997 | WO1997017937A2 Gene-therapeutic nucleic acid construct, production of same and use of same in the treatment of heart disorders |
| 05/22/1997 | WO1997017844A1 Composition for gene introduction and method for gene introduction by using the composition |
| 05/22/1997 | WO1996041606A3 Improved pharmaceutical compositions for gene therapy |
| 05/22/1997 | CA2240192A1 Methods for screening compounds that modulate cholesterol transport |
| 05/22/1997 | CA2237998A1 Chemokine from niddm pancreas |
| 05/22/1997 | CA2237528A1 Chimeric oligomers having an rna-cleavage activity |
| 05/22/1997 | CA2237400A1 Methods of treating disorders of non-visual sensory epithelia |
| 05/22/1997 | CA2236332A1 Treatment of diabetes with a glucokinase gene |
| 05/22/1997 | CA2235695A1 Inducing resistance to tumor growth with soluble igf-1 receptor |
| 05/22/1997 | CA2235629A1 Method for gene transfer into target cells with retrovirus |
| 05/21/1997 | EP0774008A1 Adenovirus including a gene coding for a superoxide dismutase |
| 05/21/1997 | EP0774005A1 Surface expression of enzyme in gene directed prodrug therapy |
| 05/21/1997 | EP0774003A1 Method of using transdominant negative retroviral integrase in the treatment of retroviral infection |
| 05/21/1997 | EP0774002A1 Dna encoding ovine adenovirus (oav287) and its use as a viral vector |
| 05/21/1997 | EP0773998A1 Novel vesicular acetylcholine carrier |
| 05/21/1997 | EP0773996A1 INTERRUPTION OF BINDING OF MDM2 AND p53 PROTEIN AND THERAPEUTIC APPLICATION THEREOF |
| 05/21/1997 | EP0773950A1 Linked peptide nucleic acids |
| 05/21/1997 | EP0773719A1 Compositions for targeting materials to cells containing androgen receptors |
| 05/21/1997 | CN1150433A Diagnosis, therapy and cellular and animal models for diseases associated with mitochondrial defects |
| 05/20/1997 | US5631360 Multistage synthesis, treatment of nucleosides, adding a n-phthaloyl group, deprotecting the hydroxy, tritylation and phosphitylation |
| 05/20/1997 | US5631359 Hairpin ribozymes |
| 05/20/1997 | US5631236 Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk |
| 05/20/1997 | US5631162 Gene expression and dna sequences |
| 05/20/1997 | US5631153 Cells and non-human organisms containing predetermined genomic modifications and positive-negative selection methods and vectors for making same |
| 05/15/1997 | WO1997017458A1 Accessory functions for use in recombinant aav virion production |
| 05/15/1997 | WO1997017456A1 In vitro construction of sv40 viruses and pseudoviruses |
| 05/15/1997 | WO1997017434A2 The use of lecithin-cholesterol acyltransferase (lcat) in the treatment of atherosclerosis |
| 05/15/1997 | WO1997017433A1 Tissue-specific and target rna-specific ribozymes |
| 05/15/1997 | WO1997017430A1 Reconstituted mineralized cartilage tissue |
| 05/15/1997 | WO1997017369A2 Dna comprising a neuron-specific transcriptional promoter and its use in a gene therapy vector |
| 05/15/1997 | WO1997017359A1 Novel promoter for vegf receptor |
| 05/15/1997 | WO1997017358A1 Mammary transforming protein |
| 05/15/1997 | WO1997017090A1 Adenovirus-mediated production of bioactive proteins by mammalian cells and animals |
| 05/15/1997 | WO1997017084A1 Drug, in particular for modulating the immunological response for the control of viruses, tumours, bacteria and parasites |
| 05/15/1997 | WO1997017063A1 Microencapsulated dna for vaccination and gene therapy |
| 05/15/1997 | WO1997016983A1 Enhancement of vascular function by modulation of endogenous nitric oxide production or activity |
| 05/15/1997 | WO1997010332A3 Chimaeric oligonucleotides and uses thereof in the identification of antisense binding sites |
| 05/15/1997 | WO1997003635A3 P16 expression constructs and their application in cancer therapy |
| 05/15/1997 | DE19541679A1 Gene transfer systems containing nuclear localisation sequences and or magnetisable microparticles, |
| 05/15/1997 | DE19534763C1 FMR1-verwandtes Protein FMR1-related protein |
| 05/15/1997 | CA2236807A1 Reconstituted mineralized cartilage tissue |
| 05/15/1997 | CA2235347A1 In vitro construction of sv40 viruses and pseudoviruses |
| 05/14/1997 | EP0772690A1 Recombinant virus vectors |
| 05/14/1997 | EP0772689A2 Retroviral vectors having a reduced recombination rate |
| 05/14/1997 | EP0772688A1 Sv-40 derived dna constructs comprising exogenous dna sequences |
| 05/14/1997 | EP0772681A1 Identification of a human cytomegalovirus gene involved in down-regulation of mhc class i heavy chain expression |
| 05/14/1997 | EP0772680A1 A polynucleotide herpes virus vaccine |
| 05/14/1997 | EP0772626A1 Isolated nucleic acid sequence coding for a tumor rejection antigen presented by hla-a2 |
| 05/14/1997 | EP0772625A1 Oligonucleoside compounds and methods for inhibiting tumor growth, invasion and metastasis |
| 05/14/1997 | EP0772622A1 5'-dithio-modified oligonucleotides |
| 05/14/1997 | EP0772621A2 Oligonucleotides with anti-mdr-1 gene activity |
| 05/14/1997 | EP0772620A1 Antimessenger oligonucleotides and urokinase receptor reversion of the invasive phenotype of transformed human fibroblasts by antimessenger oligonucleotide inhibition of urokinase receptor gene expression |
| 05/14/1997 | EP0772619A1 Immunomodulatory oligonucleotides |
| 05/14/1997 | EP0772455A2 Intracellular expression of carboxypeptidase g2 in enzyme prodrug therapy |
| 05/14/1997 | EP0772454A1 Antisense oligonucleotides against hepatitis b viral replication |
| 05/14/1997 | EP0772437A1 Compositions and methods for delivery of genetic material |
| 05/14/1997 | EP0615453B1 Anti-cancer immunotherapeutic vector constructs |
| 05/13/1997 | US5629413 Oligonucleotides with activity against human immunodeficiency virus |
| 05/13/1997 | US5629193 Paraoxonase |
| 05/13/1997 | US5629192 ETS1 gene: a human tumor suppressor gene |
| 05/13/1997 | US5629184 To cell cytoplasm, antisense therapy |
| 05/13/1997 | US5629174 Dna, rna |
| 05/13/1997 | US5629166 Cancer diagnosis |
| 05/13/1997 | US5629159 Immortalization and disimmortalization of cells |
| 05/09/1997 | WO1997016548A1 NEUROGENIC DIFFERENTIATION (NeuroD) GENES AND PROTEINS |
| 05/09/1997 | WO1997016538A1 (-)-strand rna virus vector having autonomously replicating activity |
| 05/09/1997 | WO1997016535A2 METHODS FOR USE OF Mpl LIGANDS WITH PRIMITIVE HUMAN STEM CELLS |
| 05/09/1997 | WO1997016531A1 Immunity against pasteurella haemolytica leukotoxin |
| 05/09/1997 | WO1997016459A1 Use of protein gax for treating cancer |
| 05/09/1997 | WO1997016457A2 Anti-tumoral protein |